Vijaya Diagnostic Centre Raises FY27 EBITDA Margin Guidance to 42%

Market snapshot: Vijaya Diagnostic Centre has officially revised its FY27 EBITDA margin guidance upward to 42%, compared to its previous expectation of 40%. The revision comes on the back of operational efficiencies and sustained margin expansion in recent quarters.

Data Snapshot

• Revised FY27 EBITDA margin guidance stands at 42%, up from the baseline guidance of 40%.
• In Q1 FY27, Vijaya Diagnostic reported an EBITDA margin of 42.7% with total EBITDA reaching ₹98 crore.
• Q1 FY27 PAT recorded at ₹53 crore, representing a 37.6% YoY growth with a PAT margin of 23%.

What's Changed

• FY27 EBITDA margin guidance increased by 200 bps to 42% from 40%.
• Demonstrated margin trajectory progression following 42.7% EBITDA margin delivered in Q1 FY27.

Key Takeaways

• Management raised profitability guidance for FY27 on strong operational momentum.
• High B2C revenue mix and hub expansion continue to generate positive operating leverage.
• Execution capabilities in regional centers support elevated profitability targets without compromising capital efficiency.

SAHI Perspective

The 200 bps guidance increase underscores management's confidence in sustained pricing power and volume expansion. Vijaya Diagnostic's strong integrated radiology and pathology model allows it to generate industry-leading margins while expanding its geographic footprint into non-core markets.

Market Implications

The upward guidance revision provides a positive catalyst for valuation multiples in the diagnostic sector, reinforcing investor preference for B2C-focused diagnostic operators with integrated diagnostic capabilities.

Trading Signals

Market Bias: Bullish

Management raised FY27 EBITDA margin guidance to 42% from 40%, backed by Q1 FY27 EBITDA growth of 34% YoY to ₹98 crore and strong operating leverage across core centers.

Overweight: Healthcare Services, Diagnostics Chains

Trigger Factors:

• Sustained quarterly EBITDA margin performance above 40%
• Volume growth across new geographic hubs
• Inorganic hub consolidation accretive to operating earnings

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian diagnostic sector is benefiting from shift toward organized B2C chains with integrated pathology and radiology services. Integrated operators maintain structural margin advantages over pure-play pathology players.

Key Risks to Watch

• Gestation lag and initial drag from new hub additions in expansion markets
• Regulatory interventions on test pricing thresholds
• Heightened pricing competition in regional markets

Recent Developments

In September 2026, Vijaya Diagnostic concluded the slump sale acquisition of Arya Wellness Centre in Guwahati at a valuation of ~8–9x FY26 EBITDA to establish its operational base in the North-East region. Previously in August 2026, the company posted Q1 FY27 EBITDA of ₹98 crore, representing a 34% YoY increase with margins reaching 42.7%.

Closing Insight

Upward margin revisions alongside steady network expansion signal robust core operational health, positioning Vijaya Diagnostic to maintain premium margins in the healthcare diagnostics segment.

High Performance Trading with SAHI.